Healthcare Business Investment Opportunities

Proposed pharmaceutical marketing startup focused on medicines, dietary supplements, and medical devices. - Planned operations based in Tbilisi, targeting pharmacy-led and doctor-referred demand. - Business will collaborate with European manufacturers to import and market approved products locally. - Revenue model centered on pharma marketing and distribution rather than in-house manufacturing. - Sales and promotion will be driven by medical representatives engaging doctors and pharmacies. - Currently at ideation and setup stage with no commercial operations or revenue. - Legal structure planned as a Limited Liability Company (LLC). - Promoted by a founder with over a decade of experience in the pharmaceutical industry. - The founder has previously built and scaled another pharmaceutical company and continues to operate it. - The business is not yet registered.

Proposed pharmaceutical marketing startup focused on medicines, dietary supplements, and medical devices. - Planned operations based in Tbilisi, targeting pharmacy-led and doctor-referred demand. - Business will collaborate with European manufacturers to import and market approved products locally. - Revenue model centered on pharma marketing and distribution rather than in-house manufacturing. - Sales and promotion will be driven by medical representatives engaging doctors and pharmacies. - Currently at ideation and setup stage with no commercial operations or revenue. - Legal structure planned as a Limited Liability Company (LLC). - Promoted by a founder with over a decade of experience in the pharmaceutical industry. - The founder has previously built and scaled another pharmaceutical company and continues to operate it. - The business is not yet registered.

Pre-revenue regenerative medicine company developing organ-specific decellularized ECM (extracellular matrix) hydrogel platforms for tissue regeneration. - Core technology focuses on organ-derived ECM hydrogels designed to support chronic wound healing, full-thickness wound repair, surgical recovery, and advanced tissue regeneration applications. - Product development is being carried out in collaboration with a university research partner in Japan, supporting scientific validation and translational research. - Planned commercialization strategy follows a distributor-centric expansion model, targeting rollout across up to 120 countries. - Initial international expansion is planned through cluster offices in the MENA region and Western Europe. - The business is currently in the technology development and validation phase, with no commercial revenues generated to date. - Holds a valid trade license, ensuring a compliant and structured setup for future commercialization.

Operates a pharmaceutical marketing business focused on prescription-driven sales across multiple headquarters. - Products are promoted strictly through doctor prescriptions, covering therapeutic segments such as cough & cold, pain management, antibiotics, respiratory care, and nutritional supplements. - Backed by 20–25 years of promoter experience in the pharmaceutical marketing and prescription-sales ecosystem. - Maintains strong relationships with doctors and healthcare professionals, enabling consistent prescription generation. - Partnered with 7 distributors who regularly procure and supply the products, ensuring steady secondary sales. - Operates under a marketing-led pharma model without manufacturing, allowing lean operations and scalability. - Holds valid GST registration and is registered with the MCA, ensuring compliant and structured business operations.

Tech-enabled B2B pharmaceutical distribution platform, focusing on simplifying pharmacy procurement from over 50 distributors. - 2,000+ pharmacies served till date. - Revenue model: 8-10% EBITDA margin on B2B sales, projected to grow. - Promoters: Founder (Forbes 30 under 30 Asia, IIT Bombay, Y-Combinator) and Co-Founder (25 years pharma distribution experience). - Backed by Bluewatch Ventures, Soma Capital, Enrission India Capital, and Goodwater. - $4.2M seed funding raised (3 years ago). - 150+ pharma brands integrated. - Business has a registration and distribution license.

The company is a retailer of medical devices and diagnostic systems. - Its top-selling products include hospital beds and MRI scanning devices. - The business serves 15 government hospitals in Zambia and sources products from dealers in China, Korea, and Australia. - Approximately 80% of revenue comes from medical equipment retail, while the remaining 20% is generated through the company acting as a building contractor for specific projects. - We have 3 permanent employees who ensure smooth operations. - The owner is based in Australia and can be contacted directly through the provided number.

Located in Central Hong Kong, the clinic specializes in advanced health treatments, focusing primarily on IV drips, Ozempic, and blood tests. - IV drips are the top-selling product, accounting for 70% of the clinic's revenue, catering to customers seeking hydration and nutrient therapy. - Ozempic, a medication used for weight management and diabetes control, represents 20% of sales, appealing to patients looking for effective health solutions. - Blood tests contribute to 10% of the clinic's sales, providing essential diagnostics for preventive health care and monitoring various medical conditions. - The clinic attracts approximately 100-200 customers per month, establishing a loyal customer base in the competitive healthcare market. - With strong sales and profitability, the clinic effectively meets the growing demand for outpatient health services in Hong Kong. - Utilizing innovative treatments and a customer-centric approach, the clinic positions itself as a leading health provider in the region, maximizing revenue through high-demand services. - Holds and operates with a valid clinic license.

Operates as a pharmaceutical manufacturing company in Ahmedabad producing cardiac-diabetic, psychotropic, neuro, and antibiotic medicines. - Serves 300+ clients across India through a cash-based business model supported by 25+ years of promoter experience. - Manufactures products under its own brand and also undertakes contract manufacturing for 12–15 companies. - Generates around 80% of revenue from its branded medicines and the remaining 20% from contract manufacturing. - Supplies products to 150+ multi-specialty hospitals across Gujarat and Maharashtra and fulfills government tenders in both states. - Drop in sales as the owner was busy, and was not able to dedicate enough time to the business. - Holds GMP, GLP, GDP, and ISO certifications along with valid GST registration and a manufacturing license.

Our venture operates a dual-channel revenue model through Shopify D2C and EU-based pharmacy/retail B2B, supported by a 3PL logistics hub in Brno. We serve an expanding base of early adopters across Europe and New Zealand, with a projected year-1 capacity to scale to 15,000 customers through digital acquisition and pharmacy distribution. We operate on a fully compliant, asset-light supply chain model, with the following foundations already in place: EU compliance completed (CPSR/CPNP) Responsible Person (RP) structure established. Unique New Zealand ingredient IP. GMP-certified contract manufacturing partners. Active market preparation and channel development. D2C Shopify and pharmacy/retail B2B distribution. Founder expertise: 20+ years in procurement, supply chain, GMP/ISO implementation, and corporate governance, supported by a Master’s in Business Administration. Our partnerships with award-winning R&D labs enable end-to-end NPD within a high-quality and premium standard production framework. The new product development process has been constrained by the partner’s abrupt withdrawal of funds. Manufacturing & fulfilment: All production is via GMP-certified contract manufacturers. Storage, pick/pack, and fulfilment managed by a 3PL warehouse in Brno, including climate-controlled storage and EU-wide distribution. Highly scalable setup enabling rapid expansion across EU markets without physical infrastructure investment. Scale & clients: 18 active B2B partners across New Zealand, the Czech Republic, and the Netherlands. 5 contract manufacturers (GMP / ISO 22716 certified). Initial B2C launch targeting 5,000–7,000 consumers in the first 12 months through the Shopify Plus EU hub. Revenue model: 70% B2B ingredient supply to EU formulators and private-label brands. 30% B2C sales via e-commerce of clean-label, daily effervescent collagen + antioxidant products. Promoter experience: 20+ years in procurement, manufacturing, and international trade. Prior leadership in supply-chain optimisation and product commercialisation across NZ, EU, and CIS markets. We work with contractors who are specialists in the EU legal framework and with a pharmaceutical-certified facility under the supervision of skilled staff to increase our earnings. Both branches operate under the same legal entity.